Drug intelligence / Profile preview

Influenza B virus Victoria lineage hemagglutinin

Development stage
Unknown
Lead developer
Viatris
Modality
Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Administration
Intramuscular, Subcutaneous, Intradermal
01

Overview

Influenza B virus Victoria lineage haemagglutinin is a recombinant or purified surface glycoprotein derived from the Victoria lineage of influenza B viruses. It is a key antigenic component used in seasonal quadrivalent and trivalent influenza vaccines to induce immunity against circulating strains of the Victoria lineage. The protein mediates viral entry by binding to sialic acid receptors on host cells and facilitating membrane fusion. Vaccines containing this antigen stimulate humoral immune responses, leading to the production of neutralizing antibodies that protect against infection with matching or closely related strains. The World Health Organization recommends inclusion of both major lineages—Victoria and Yamagata—in quadrivalent vaccines due to their distinct antigenicity and shifting prevalence[3][4][7][8].

Brand names
Influvac Tetra
Other names
B/Victoria lineage haemagglutinininfluenza B (Victoria-like) hemagglutininB/Washington/02/2019 (B/Victoria lineage)-like virus hemagglutinin
02

Targets

Sialoglycan (Cell-surface sialoglycan)HA (Hemagglutinin)

Beyond the preview

Go deeper on Influenza B virus Victoria lineage hemagglutinin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Influenza B virus Victoria lineage hemagglutinin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call